6-糠氨基嘌呤作用機制 - Medchemexpress - MCE中國

1、Product Data SheetKinetinCat. No.: HY-N0160CAS No.: 525-79-1分式: CHNO分量: 215.21作靶點: Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 33.33 mg/mL (154.87 mM; Need ultrasonic)H2O : 0.1 mg/mL (insoluble)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1

2、mM 4.6466 mL 23.2331 mL 46.4662 mL5 mM 0.9293 mL 4.6466 mL 9.2932 mL10 mM 0.4647 mL 2.3233 mL 4.6466 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內(nèi)使，-20C 儲存時，請在 1 個內(nèi)使。體內(nèi)實驗請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍浮Ｒ韵氯芙獍付颊埾劝凑?In Vitro 式配制澄清的儲備液，再依次添加助溶劑：為

3、保證實驗結果的可靠性，澄 的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (11.62 mM); Clear solution此案可獲得 2.5 mg/mL (11.62 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 40

4、0 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (11.62 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲得 2.5 mg/mL (11.62 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合均勻

5、。3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (11.62 mM); Clear solution此案可獲得 2.5 mg/mL (11.62 mM，飽和度未知) 的澄 溶液，此案不適于實驗周 期在半個以上的實驗。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 900 L 油中，混合均勻。BIOLOGICAL ACTIVITY物活性 Kinetin (N6-furfuryladenine) 屬于 N6-取代腺嘌呤衍物細胞分裂素家族，細胞分裂素 程的植物長激素。Kinetin 具有抗衰

6、作。參與細胞分裂、分化等理過體外研究 Kinetin (N6-furfuryladenine) shows to have a direct effect on superoxide dismutase activity in plants; preventoxidation of unsaturated acids in plant membranes; slow down development and aging in insects, by reducing theirfecundity and increasing the specific activity of catalase;

7、 and delay the onset of many age-related characteristics thatappear in normal human skin fibroblasts undergoing aging in vitro. Kinetin (70-150 M) markedly suppressedhydroxyl radical formation by about 41% and 76%, respectively1.The plant cytokinin kinetin dramatically increases exon 20 inclusion in

8、 RNA isolated from cultured familialdysautonomia (FD) cells2.體內(nèi)研究 Kinetin (N6-furfuryladenine) (2-6 mg/kg; injection into the tail vein) effectively prevents ADP-induced acutepulmonary thrombosis in mice1.Subjects received 23.5 mg/kg/d for 28 d. An increase in WT IKBKAP mRNA expression in leukocytes

9、 was noted after 8d in six of eight individuals; after 28 d, the mean increase compared with baseline was significant3.Animal Model: ADP-induced acute pulmonary thrombosis 20-24 g mice (ICR strain)1Dosage: 2, 4, 6 mg/kgAdministration: Injection into the tail veinResult: Reduced mortality to 70%, 40%

10、 and 35% at 2, 4, and 6 mg/kg, respectively.REFERENCES1. Hsiao G, et al. Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo. Eur J Pharmacol.2003 Apr 4;465(3):281-7.2. Axelrod FB, et al. Kinetin improves IKBKAP mRNA splicing in

11、patients with familial dysautonomia. Pediatr Res. 2011 Nov;70(5):480-3.3. Hims MM, et al. Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med (Berl).2007 Feb;85(2):149-61.4. Griffaut B, et al. Cytotoxic effects of kinetin riboside on mouse, human and plant tumour cells. Int J Biol Macromol. 2004 Aug;34(4):271-5.McePdfHeightPage 2 of 3 www.MedChemECaution: Product has not been fully val